Viridian Therapeutics, Inc.DE - Common Stock (VRDN)
CUSIP: 92790C104
Q2 2022 13F Holders as of 30 Jun 2022
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 95,489,675
- Total 13F shares
- 28,321,810
- Share change
- +3,393,521
- Total reported value
- $327,687,712
- Price per share
- $11.57
- Number of holders
- 80
- Value change
- +$27,237,558
- Number of buys
- 51
- Number of sells
- 37
Quarterly Holders Quick Answers
What is CUSIP 92790C104?
CUSIP 92790C104 identifies VRDN - Viridian Therapeutics, Inc.DE - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 92790C104:
Top shareholders of VRDN - Viridian Therapeutics, Inc.DE - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VR Adviser, LLC |
13F
|
Company |
1.9%
|
1,852,919
|
$34,260,000 | — | 31 Mar 2022 | |
| BVF INC/IL |
13F
|
Company |
1.8%
|
1,744,012
|
$32,247,000 | — | 31 Mar 2022 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
1.8%
|
1,739,530
|
$32,164,000 | — | 31 Mar 2022 | |
| Frazier Life Sciences Public Fund, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,505,200
|
$31,609,200 | — | 23 Sep 2021 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
1.5%
|
1,423,053
|
$26,312,000 | — | 31 Mar 2022 | |
| TCG Crossover Management, LLC |
13F
|
Company |
1.4%
|
1,314,000
|
$24,296,000 | — | 31 Mar 2022 | |
| Vivo Capital, LLC |
13F
|
Company |
1.4%
|
1,300,000
|
$24,037,000 | — | 31 Mar 2022 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
1.3%
|
1,256,051
|
$23,224,000 | — | 31 Mar 2022 | |
| Deep Track Capital, LP |
13F
|
Company |
1.2%
|
1,170,290
|
$21,639,000 | — | 31 Mar 2022 | |
| Avidity Partners Management LP |
13F
|
Company |
1.1%
|
1,040,000
|
$19,230,000 | — | 31 Mar 2022 | |
| Cormorant Asset Management, LP |
13F
|
Company |
1%
|
1,000,000
|
$18,490,000 | — | 31 Mar 2022 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
1%
|
975,618
|
$18,039,000 | — | 31 Mar 2022 | |
| Commodore Capital LP |
13F
|
Company |
1%
|
951,339
|
$17,590,000 | — | 31 Mar 2022 | |
| Fairmount Funds Management LLC |
13F
|
Company |
0.99%
|
944,092
|
$17,456,000 | — | 31 Mar 2022 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.99%
|
941,218
|
$17,403,000 | — | 31 Mar 2022 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.99%
|
940,577
|
$17,391,000 | — | 31 Mar 2022 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.82%
|
783,095
|
$14,479,000 | — | 31 Mar 2022 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.63%
|
600,023
|
$11,094,000 | — | 31 Mar 2022 | |
| Kynam Capital Management, LP |
13F
|
Company |
0.62%
|
589,826
|
$10,906,000 | — | 31 Mar 2022 | |
| Ally Bridge Group (NY) LLC |
13F
|
Company |
0.52%
|
496,012
|
$9,171,000 | — | 31 Mar 2022 | |
| Ghost Tree Capital, LLC |
13F
|
Company |
0.49%
|
466,403
|
$8,624,000 | — | 31 Mar 2022 | |
| ACUTA CAPITAL PARTNERS, LLC |
13F
|
Company |
0.36%
|
340,000
|
$6,287,000 | — | 31 Mar 2022 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.31%
|
300,000
|
$5,547,000 | — | 31 Mar 2022 | |
| Woodline Partners LP |
13F
|
Company |
0.23%
|
221,257
|
$4,091,000 | — | 31 Mar 2022 | |
| Atlas Venture Advisors, Inc. |
13F
|
Company |
0.22%
|
209,505
|
$3,874,000 | — | 31 Mar 2022 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.21%
|
199,238
|
$3,683,000 | — | 31 Mar 2022 | |
| Walleye Capital LLC |
13F
|
Company |
0.17%
|
162,281
|
$3,001,000 | — | 31 Mar 2022 | |
| Eversept Partners, LP |
13F
|
Company |
0.16%
|
155,743
|
$2,879,688 | — | 31 Mar 2022 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.16%
|
152,775
|
$2,825,000 | — | 31 Mar 2022 | |
| SILVERARC CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.13%
|
126,136
|
$2,332,000 | — | 31 Mar 2022 | |
| PURA VIDA INVESTMENTS, LLC |
13F
|
Company |
0.11%
|
105,460
|
$1,950,000 | — | 31 Mar 2022 | |
| ExodusPoint Capital Management, LP |
13F
|
Company |
0.1%
|
97,745
|
$1,807,000 | — | 31 Mar 2022 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.1%
|
97,527
|
$1,803,000 | — | 31 Mar 2022 | |
| Atlas Venture Life Science Advisors, LLC |
13F
|
Company |
0.09%
|
90,072
|
$1,665,000 | — | 31 Mar 2022 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
0.09%
|
90,000
|
$1,664,000 | — | 31 Mar 2022 | |
| Endurant Capital Management LP |
13F
|
Company |
0.09%
|
83,217
|
$1,539,000 | — | 31 Mar 2022 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.07%
|
66,598
|
$1,231,000 | — | 31 Mar 2022 | |
| STATE STREET CORP |
13F
|
Company |
0.07%
|
66,000
|
$1,220,000 | — | 31 Mar 2022 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.06%
|
61,518
|
$1,137,000 | — | 31 Mar 2022 | |
| Squarepoint Ops LLC |
13F
|
Company |
0.06%
|
61,390
|
$1,135,000 | — | 31 Mar 2022 | |
| Polar Asset Management Partners Inc. |
13F
|
Company |
0.06%
|
59,700
|
$1,104,000 | — | 31 Mar 2022 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.06%
|
56,487
|
$1,044,000 | — | 31 Mar 2022 | |
| LMR Partners LLP |
13F
|
Company |
0.06%
|
52,774
|
$976,000 | — | 31 Mar 2022 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.05%
|
50,000
|
$925,000 | — | 31 Mar 2022 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.05%
|
50,000
|
$925,000 | — | 31 Mar 2022 | |
| HighVista Strategies LLC |
13F
|
Company |
0.05%
|
49,065
|
$907,000 | — | 31 Mar 2022 | |
| MORGAN STANLEY |
13F
|
Company |
0.04%
|
34,929
|
$646,000 | — | 31 Mar 2022 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.03%
|
33,187
|
$614,000 | — | 31 Mar 2022 | |
| CITIGROUP INC |
13F
|
Company |
0.03%
|
28,140
|
$520,000 | — | 31 Mar 2022 | |
| Maven Securities LTD |
13F
|
Company |
0.03%
|
27,486
|
$508,000 | — | 31 Mar 2022 |
Institutional Holders of Viridian Therapeutics, Inc.DE - Common Stock (VRDN) as of Q2 2022
As of 30 Jun 2022,
Viridian Therapeutics, Inc.DE - Common Stock (VRDN) was held by
80 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
28,321,810 shares.
The largest 10 holders included
VR Adviser, LLC, BVF INC/IL, COMMODORE CAPITAL LP, BlackRock Inc., VANGUARD GROUP INC, TCG Crossover Management, LLC, Paradigm Biocapital Advisors LP, Vivo Capital, LLC, Deep Track Capital, LP, and MILLENNIUM MANAGEMENT LLC.
This page lists
80
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2022 vs Q1 2022 Across Filers
Q1 2022 holders
71
Q2 2022 holders
80
Holder diff
9
| Investor | Q1 2022 Shares | Q2 2022 Shares | Share Diff | Share Chg % | Q1 2022 Value $ | Q2 2022 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.